About this medicine

Rivastigmine is a symptomatic dementia medicine available in oral and skin-patch formulations. They contain the same active substance but are not equivalent milligram-for-milligram. A patch's delivery rate differs from the total medicine stored inside it; confusing the two creates a serious dosing risk.

What is this medicine used for?

The checked oral products cover mild to moderately severe Alzheimer's dementia and dementia associated with idiopathic Parkinson's disease. The checked Exelon patch licence covers Alzheimer's dementia only. Do not transfer the oral Parkinson's indication automatically to the patch or present off-label use as licensed.

Which warning signs need help?

Wear only one patch at a time and remove the old one before applying a replacement. If multiple patches are found or overdose is suspected, remove them and obtain urgent medical advice; do not apply another for 24 hours. Severe vomiting, collapse, a very slow pulse or breathing difficulty require urgent assessment.

How do I take it safely?

Oral reference dosing starts at 1.5 mg twice daily with food, increasing no faster than every two weeks through 3, 4.5 and 6 mg twice daily as tolerated. The oral maximum is 6 mg twice daily. These are prescribed dose steps, not a list of verified capsule pack strengths.

The patch starts at 4.6 mg/24 h and usually moves to 9.5 after at least four weeks. A 13.3 mg/24 h patch is considered only after at least six months at 9.5 with acceptable tolerability and meaningful cognitive or functional decline. A clinician manages any oral-to-patch switch.

What side effects should I know about?

Nausea, vomiting, diarrhoea, reduced appetite and weight loss are important practical problems. The patch can cause local irritation. Persistent vomiting or diarrhoea may lead to dehydration; report poor intake, dizziness, falls or worsening movement symptoms promptly.

Who needs extra care with this medicine?

Spreading patch redness, blisters or a reaction not improving within 48 hours of removal suggests allergic contact dermatitis: stop treatment and obtain advice. Oral substitution requires negative allergy testing and close medical supervision. Slow pulse, ulcer disease, asthma, urinary obstruction and seizures also need review.

Can it affect my other medicines?

Beta-blockers and other pulse-slowing medicines can increase fainting risk. Other cholinergic medicines add effects, while anticholinergic drugs may oppose treatment. Metoclopramide can worsen movement problems. Anaesthetic teams need to know about rivastigmine because some muscle-relaxant effects may be prolonged.

What check-ups will I need?

Monitor benefit, pulse, weight and adverse effects, including correct patch use. SPS recommends baseline pulse, electrolytes, weight and liver tests, with renal assessment for rivastigmine; pulse is checked monthly after starting or changing dose and six-monthly when stable. ECG review is risk-based.

What about pregnancy, breastfeeding and age?

There is no relevant paediatric dementia indication. Pregnancy use is reserved for clear necessity in the checked information, and breastfeeding is not recommended. Kidney or liver impairment and body weight below 50 kg require careful tolerability assessment rather than a universal dose copied from another formulation.

What if I miss a dose or want to stop?

If treatment has stopped for more than three days, contact the prescriber before restarting: oral treatment restarts low, and patches restart at 4.6 mg/24 h under the product instructions. Rotate application sites, avoid repeating the same site for 14 days and never cut a patch.

Apply to clean, dry, intact skin; avoid prolonged external heat. Wash hands after handling, fold used patches sticky-side inwards, and keep them away from children and pets.

How does it work?

Rivastigmine slows the breakdown of acetylcholine, a chemical messenger used by brain cells. It inhibits acetylcholinesterase and butyrylcholinesterase, meaning it temporarily reduces the activity of two enzymes, proteins that help break the messenger down. This leaves more acetylcholine available to communicate with other cells.

Communication using acetylcholine is called cholinergic, so supporting cholinergic pathways means helping connected cells that still use this messenger. That can help with symptoms, but it does not replace lost nerve cells or show that the underlying disease has stopped. The person’s memory, thinking and daily activities remain important when assessing benefit.

How does it affect my body?

Greater cholinergic activity can affect the gut, pulse and movement as well as cognition. In Parkinson's dementia, tremor or other movement symptoms may worsen. Low body weight and reduced eating matter because adverse effects and exposure can become more troublesome.

How does my body process it?

Cholinesterase-mediated hydrolysis is the main metabolic route, with relatively little involvement of major CYP enzymes. Metabolites leave largely through urine. Oral and patch concentration profiles differ; a lower CYP interaction burden does not remove important pharmacodynamic interactions.

How do treatment options differ?

NICE includes rivastigmine alongside donepezil and galantamine for mild-to-moderate Alzheimer's disease. A patch may change administration demands, but does not remove the need for caregiver oversight. NHS access and selection depend on the relevant national and local pathway, not just the existence of a licence.

A closer look at the science

As a carbamate, rivastigmine temporarily forms a complex with its target enzymes. Enzyme inhibition lasts longer than its short oral plasma half-life. The patch delivers the same molecule more slowly; it is a delivery-system difference, not a distinct brain receptor treatment.

How was this medicine developed?

MHRA's June 2010 warning highlighted overdose from forgotten old patches or multiple patches. It explains why formulation-specific administration safeguards remain central to current practice; a delivery-system change does not make a medicine intrinsically free of serious dosing errors.

Sources and References

  1. Exelon 4.6, 9.5 and 13.3 mg/24 h patches: SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom; guideline implementation varies by nation.

  2. Rivastigmine Sandoz 1.5 mg hard capsules: SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom; guideline implementation varies by nation.

  3. Rivastigmine Sandoz 2 mg/ml oral solution: SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom; guideline implementation varies by nation.

  4. Exelon transdermal patches: patient leaflet

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom; guideline implementation varies by nation.

  5. Rivastigmine (Exelon) transdermal patch: risk of medication errors

    Scope: United Kingdom; guideline implementation varies by nation.

  6. Acetylcholinesterase inhibitors monitoring

    Scope: United Kingdom; guideline implementation varies by nation.

  7. NICE TA217: What has NICE said?

    Scope: United Kingdom; guideline implementation varies by nation.

  8. Exelon Patch (rivastigmine): prescribing information — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: 12.1 Mechanism of Action; 12.3 Pharmacokinetics. This does not establish UK product authorisation or prescribing..

  9. Rivastigmine tartrate capsules: prescribing information — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: 12.1 Mechanism of Action; 12.3 Pharmacokinetics. This does not establish UK product authorisation or prescribing..

  10. Rivastigmine: MedlinePlus Drug Information — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: Why is this medication prescribed?; How should this medicine be used?. This does not establish UK product authorisation or prescribing..

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top